Síndrome multisistémico inflamatorio pediátrico (MIS-C/PIMS): bases inmunológicas que sustentan el tratamiento
Resumen
El síndrome multisistémico inflamatorio pediátrico, temporalmente asociado a COVID-19 (MIS-C/PIMS), es una nueva condición post-infecciosa secundaria a la infección por SARS-CoV2. Se ha caracterizado por una respuesta inflamatoria con afección multisistémica, con involucro de varios mecanismos de daño inmunológico como el incremento exagerado de citocinas y el daño epitelial. El tratamiento inmunomodulador está dirigido a controlar las manifestaciones de hiperinflamación, para estabilizar y prevenir secuelas a largo plazo.
PALABRAS CLAVE: COVID-19, tratamiento inmunomodulador, inmunología, gammaglobulina, Enfermedad de Kawasaki, SARS-CoV-2, síndrome multisistémico inflamatorio pediátrico (MIS-C /PIMS)
Citas
Buonsenso D, Riitano F, Valentini P. Pediatric Inflammatory Multisystem Syndrome Temporally Related With SARS-CoV-2: Immunological Similarities With Acute Rheumatic Fever and Toxic Shock Syndrome. Front Pediatr. 2020;8(September):1–5.
Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. Children. 2020;7(7):69.
Lawrensia S, Henrina J, Wijaya E, Suciadi LP, Saboe A, Cool CJ. Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: a New Challenge amid the Pandemic. SN Compr Clin Med. 2020;2(11):2077–85.
Cheng MH, Zhang S, Porritt RA, Arditi M, Bahar I. An insertion unique to SARS-CoV-2 exhibits superantigenic character strengthened by recent mutations. bioRxiv. 2020;1:1–6.
Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R, Lachaume N, et al. Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): A multicentre cohort. Ann Rheum Dis. 2020;79(8):999–1006.
Felsenstein S, Willis E, Lythgoe H, McCann L, Cleary A, Mahmood K, et al. Presentation, Treatment Response and Short-Term Outcomes in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). J Clin Med. 2020;9(10):3293.
Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M, et al. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- research that is available on the COVID-19 resource centre - including this for unrestricted research re-use a. 2020;(January):19–21.
Jonat B, Gorelik M, Boneparth A, Geneslaw AS, Zachariah P, Shah A, et al. Multisystem Inflammatory Syndrome in Children Associated With Coronavirus Disease 2019 in a Children’s Hospital in New York City. Pediatr Crit Care Med. 2020 Sep 29;Publish Ah:1–14.
Elias MD, McCrindle BW, Larios G, Choueiter NF, Dahdah N, Harahsheh AS, et al. Management of Multisystem Inflammatory Syndrome in Children Associated With COVID-19: A Survey From the International Kawasaki Disease Registry. CJC Open. 2020;2(6):632–40.
Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N Engl J Med. 2020 Jul 23;383(4):334–46.
Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Vol. 72, Arthritis and Rheumatology. 2020. 1791–1805 p.
Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, Lorrot M, et al. Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children. JAMA. 2021;1–10.
Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM, El Chebib H, et al. Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients. J Pediatric Infect Dis Soc. 2020 Dec 31;9(6):716–37.
Dove ML, Jaggi P, Kelleman M, Abuali M, Ang JY, Ballan W, et al. Multisystem Inflammatory Syndrome in Children: Survey of Protocols for Early Hospital Evaluation and Management Matthew. J Pediatr. 2021;229(February):33–40.
De Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T, Bader-Meunier B, et al. European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease-the SHARE initiative. Rheumatol (United Kingdom). 2019;58(4):672–82.
Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, Mcdonald DR. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution! Clin Immunol. 2020;(January).
Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(4):968-981.e7.
Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, Angoulvant F, et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris , France : prospective observational study. 2020;1–7.
Shukur Wasman Smail, Muhammad Saeed, Twana alkasalias, Zhikal Omar Khudhur Delan Ameen Younus, Mustafa Fahmi Rajab, Wayel Habib Abdulahad, Hafiz Iftikhar Hussain, Kamal Niaz MS. Inflammation, immunity and potential target therapy of SARS-COV-2: a total scale analysis review. Food Chem Toxicol. 2021;
Sood M, Sharma S, Sood I, Sharma K, Kaushik A. Emerging Evidence on Multisystem Inflammatory Syndrome in Children Associated with SARS-CoV-2 Infection: a Systematic Review with Meta-analysis. SN Compr Clin Med. 2021;3(1):38–47.
Calò Carducci FI, De Ioris MA, Agrati C, Carsetti R, Perrotta D, D’Argenio P, et al. Hyperinflammation in Two Severe Acute Respiratory Syndrome Coronavirus 2-Infected Adolescents Successfully Treated With the Interleukin-1 Inhibitor Anakinra and Glucocorticoids. Front Pediatr. 2020;8(November):1–6.
Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et al. COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines; a Western New York approach. Prog Pediatr Cardiol. 2020;57(May).
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc. 2020;323(18):1824–36.
Wurth R, Hajdenberg M, Barrera FJ, Shekhar S, Gharib OAM, Porter F, et al. Scoping review of COVID-19- related systematic reviews and meta- analyses : can we really have confidence in their results ? Postgr Med J Epub. 2021;1–8.
Shubhi Kaushik, MBBS1,*, Scott I. Aydin, MD1, 2,*, Kim R. Derespina, MD3, PrernaB.Bansal, MD2, Shanna Kowalsky D, Rebecca Trachtman, MD5, JenniferK.Gillen, MD1, Michelle M. Perez, MD3, Sara H. Soshnick, DO, MS3, Edward E. Conway, Jr., MD6, Asher Bercow, MD6, HowardS.Seiden, MD2, Robert H.Pass, MD2, Henry M. Ushay, MD, PhD3, George Ofori-Amanfo, MD1, 2, and Shivanand 7, Objective. Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City. J Pediatr. 2020;224:24–9.
Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H, Poli-Harlowe C, Tapia LI, Ortiz-Fritz P. Pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 treated with tocilizumab. Pediatr Rep. 2020;12(3):142–8.
Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig. 2020 Jun 26;40(6):511–8.
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: A scientific statement for health professionals from the American Heart Association. Vol. 135, Circulation. 2017. 927–999 p.
Abdel-Haq N, Asmar BI, Deza Leon MP, McGrath EJ, Arora HS, Cashen K, et al. SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment. Eur J Pediatr. 2021;
